Madrigal Pharmaceuticals, Inc. Stock News

Integrating Echosens’ FibroScan into MetaPhy’s Chronic Care Liver Disease Management Program Impacts Patient Outcomes, Costs, Financial Performance

GENFIT S A/ADR (NASDAQ: GNFT) is one of 141 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare GENFIT S A/AD

In this article you are going to find out whether hedge funds think Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a good investment right now. We like to check what the smart money thinks first befo

Inventiva SA has filed to raise $90 million in a U.S. IPO. The firm is advancing a pipeline of treatment candidates for NASH, MPS and other diseases. IVA is pre

Madrigal Pharmaceuticals (NASDAQ:MDGL)‘s stock had its “buy” rating restated by stock analysts at Oppenheimer in a research report issued to clients and investors on Wednesday, AnalystRatings.co

GENFIT S A/ADR (NASDAQ: GNFT) is one of 141 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare GENFIT S A/AD

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25) Brainstorm Cell...

India VIX moved up 0.51% from 29.57 to 29.73 level.

Algernon Pharmaceuticals Inc. (CSE: AGN | OTCQB: AGNPF | FSE: AGW) is a clinical stage drug development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney di…

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Tetraphase (TTPH – Research Report) today. The company’s shares closed

In a report released today, Ed Arce from H.C. Wainwright initiated coverage with a Hold rating on Intercept Pharma (ICPT

Regulatory News : POXEL SA (Paris:POXEL) (Euronext : POXEL - FR0012432516), société biopharmaceutique spécialisée dans le développement de traitements

Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Momenta Pharma (MNTA – Research Report) today. The company’s shares

Read about the biggest pharmaceutical development and pricing stories from the past week in KHN’s Prescription Drug Watch roundup.